Epidemiology and Clinical Features of Adult Patients with Psoriasis in Malaysia: 10-Year Review from the Malaysian Psoriasis Registry (2007–2016)

Table 2

Types of treatment and outcome.

Type of therapy	Baseline/first visit; ( = 15,635)		Last follow-up; (6 months and above); ( = 5,701)
		%		%
Topical	14,741	93.6	5,441	95.4
Topical steroids	13,079	89.4	5,022	92.3
Emollient	11,526	78.8	4,360	80.1
Tar preparation	10,546	72.1	3,789	69.6
Keratolytics	8,089	55.3	3,069	56.4
Calcipotriol	2,410	16.5	968	17.8
Calcipotriol with betamethasone dipropionate	2,202	15.1	818	15.0
Dithranol	242	1.7	100	1.8
Others	208	1.4	60	1.1
Phototherapy	449	2.9	184	1.2
NB-UVB	391	87.1	169	91.8
BB-UVB	28	6.2	7	3.8
Oral PUVA	12	2.7	4	2.2
Topical PUVA	7	1.6	2	1.1
Bath PUVA	4	0.9	3	1.6
Excimer laser	1	0.2	0	0.0
Others	14	3.1	5	2.7
Systemic therapy	2,910	18.5	1,405	8.9
Methotrexate	2,154	78.0	1,012	72.0
Acitretin	515	18.7	276	19.6
Sulphasalazine	176	6.4	67	4.8
Cyclosporin	120	4.3	56	4.0
Systemic corticosteroids	108	3.9	24	1.7
Hydroxyurea	18	0.7	3	0.2
Biologics	90	3.3	34	2.4
Ustekinumab	31	36.5	11	32.4
Adalimumab	25	29.4	8	23.5
Etanercept	14	16.5	7	20.6
Infliximab	3	3.5	2	5.9
Golimumab	4	4.7	1	2.9
Efalizumab	1	1.2	0	0.0
Secukinumab	2	2.4	0	0.0
Severity of psoriasis
BSA < 5%	1,826	25.2	666	25.7
BSA 5–10%	3,725	51.4	1,284	49.6
BSA > 10–90%	1,572	21.7	598	23.1
BSA > 90%	131	1.8	43	1.7
Mean DLQI	8.51 ± 6.58		8.29 ± 6.56